Panolos Bioscience is a frontrunner in structure-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapies targeting cancer, autoimmune, and rare diseases. Our proprietary "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) technology" features a VEGF receptor backbone, enabling the creation of mono- or multi-specific antibody therapeutics with enhanced efficacy. 
Starting October 2023, PB101 using αART technology is enrolling for Phase I which is manufactured by Samsung Biologics based on a CDMO partnership. Panolos attracted a development partnership with Kelun-Biotech for PB203 (aka, PKB01), and formed the strategic alliance and CDMO partnership with Chime Biologics for the same. Panolos is developing various pipelines targeting PD-L1, EGFR, and TGF-beta(b)
To support our ongoing development, Panolos Bioscience raised $18 million in Series A funding and is currently seeking a Series B Bridge investment of $20 million in 2023.

Panolos Bioscience

Hyeseong Lim

This department oversees the strategic direction and operational management of the organization.

Panolos Bioscience

Org chart

Teams

Executive Leadership

Offices

Panolos Bioscience

Org chart

Teams

Executive Leadership

Offices

Related companies